Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Long-Term Debt Repayments (2016 - 2025)

Marimed (MRMD) has disclosed Long-Term Debt Repayments for 8 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.6 million, a N/A change, with the full-year FY2023 number at $5.5 million, changed N/A from a year prior.
  • Long-Term Debt Repayments was $1.5 million for Q3 2025 at Marimed, down from $1.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $15.3 million in Q2 2021 to a low of $2294.0 in Q3 2021.
  • A 3-year average of $3.3 million and a median of $1.5 million in 2025 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 2086.0% in 2021; the steepest drop was 99.54% in 2021.
  • Marimed's Long-Term Debt Repayments stood at $619727.0 in 2021, then skyrocketed by 787.97% to $5.5 million in 2023, then tumbled by 72.74% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Long-Term Debt Repayments are $1.5 million (Q3 2025), $1.6 million (Q2 2025), and $1.5 million (Q1 2025).